AU2001281416A1 - Transportation of nucleic acid substances - Google Patents

Transportation of nucleic acid substances

Info

Publication number
AU2001281416A1
AU2001281416A1 AU2001281416A AU8141601A AU2001281416A1 AU 2001281416 A1 AU2001281416 A1 AU 2001281416A1 AU 2001281416 A AU2001281416 A AU 2001281416A AU 8141601 A AU8141601 A AU 8141601A AU 2001281416 A1 AU2001281416 A1 AU 2001281416A1
Authority
AU
Australia
Prior art keywords
acid
nucleic acid
administration
group
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281416A
Inventor
Petrus Johannes Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pitmy International NV
Original Assignee
Pitmy Internat N V
Pitmy International NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pitmy Internat N V, Pitmy International NV filed Critical Pitmy Internat N V
Publication of AU2001281416A1 publication Critical patent/AU2001281416A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/60—Isolated nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Biochemistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention provides for a method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism the method being characterised in that the nucleic acid substance is formulated with an administration medium which comprises a solution of nitrous oxide gas in a physiologically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linoelic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5 3], decosahexaenoic acid [C22: 6 3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil, with ethylene oxide.
AU2001281416A 2000-07-19 2001-07-19 Transportation of nucleic acid substances Abandoned AU2001281416A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA2000/3643 2000-07-19
ZA200003643 2000-07-19
PCT/ZA2001/000100 WO2002005849A2 (en) 2000-07-19 2001-07-19 Transportation of nucleic acid substances

Publications (1)

Publication Number Publication Date
AU2001281416A1 true AU2001281416A1 (en) 2002-01-30

Family

ID=25588832

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001281415A Abandoned AU2001281415A1 (en) 2000-07-19 2001-07-19 Enhancement of the action of central and peripheral nervous system agents
AU2001281416A Abandoned AU2001281416A1 (en) 2000-07-19 2001-07-19 Transportation of nucleic acid substances

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001281415A Abandoned AU2001281415A1 (en) 2000-07-19 2001-07-19 Enhancement of the action of central and peripheral nervous system agents

Country Status (7)

Country Link
EP (2) EP1476195B1 (en)
AT (1) ATE480246T1 (en)
AU (2) AU2001281415A1 (en)
CA (2) CA2416650C (en)
DE (1) DE60143058D1 (en)
DK (1) DK1476171T3 (en)
WO (2) WO2002005849A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375267T3 (en) * 2005-01-28 2012-02-28 North-West University COMBINATION OF LIPIDS AND NITROUS OXIDE AS AN ASSISTANT TO POWER THE EFFECTIVENESS OF VACCINES.
AU2016266011B2 (en) * 2006-02-27 2017-11-16 North-West University Plant supporting formulation, vehicle for the delivery and translocation of phytologically beneficial substances and compositions containing same
BRPI0708325A2 (en) * 2006-02-27 2011-05-24 Univ Northwest plant support formulation, vehicle for the distribution and displacement of phytologically beneficial substances, and compositions containing the same
DE102006032427A1 (en) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Use of composition comprising e.g. clozapine, quetiapine, olanzapine, benzyl- and/or phenylethyl alcohol, ethanol, ethereal oil, sweetener, and polyethylene glycol, for preparing an orally administering solution to treat schizophrenia
DE102006032426A1 (en) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Use of a composition comprising e.g. clozapine and quetiapine; benzyl- and/or phenylethyl alcohol; propylene glycol; ethereal oil; and polyethylene glycol, for preparing an orally administering solution to treat schizophrenia
US20100297249A1 (en) * 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CA2827336C (en) 2011-02-23 2016-01-26 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
CA2850964C (en) 2011-10-05 2021-02-02 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
JP6475733B2 (en) 2013-09-06 2019-02-27 ザ ユニバーシティー オブ モンタナ Method for reducing neuronal cell death using haloalkylamine
WO2015063746A1 (en) * 2013-11-04 2015-05-07 The South African Nuclear Energy Corporation Limited Pharmaceutical composition
US20150306063A1 (en) * 2014-04-25 2015-10-29 Diane McGINNIS Composition and method for vaginal therapy
US10786192B2 (en) 2016-10-19 2020-09-29 Rutgers, The State University Of New Jersey System and method for determining amount of volition in a subject
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
NL2022082B1 (en) * 2018-11-28 2020-06-25 Univ Free State Transport vessels for facilitating trans-membrane transport
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin
EP4397371A2 (en) 2020-05-19 2024-07-10 Cybin IRL Limited Deuterated tryptamine derivatives and methods of use
AU2023207084A1 (en) * 2022-01-16 2024-07-18 Winsantor, Inc. Compositions and methods for improving sexual sensory disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2132236T3 (en) * 1992-06-08 1999-08-16 Pitmy Int Nv DERMATOLOGICAL COMPOSITION CONTAINING NITROUS OXIDE.
AU730495B2 (en) * 1995-11-13 2001-03-08 North West University Administration media for analgesic, antiinflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs

Also Published As

Publication number Publication date
WO2002005851A8 (en) 2002-12-27
ATE480246T1 (en) 2010-09-15
EP1476171B1 (en) 2010-09-08
CA2416519C (en) 2011-09-20
EP1476195A2 (en) 2004-11-17
CA2416650C (en) 2010-09-21
WO2002005849A2 (en) 2002-01-24
WO2002005849A3 (en) 2002-07-25
WO2002005851A3 (en) 2002-08-08
DK1476171T3 (en) 2011-01-10
WO2002005851A2 (en) 2002-01-24
EP1476171A2 (en) 2004-11-17
CA2416650A1 (en) 2002-01-24
CA2416519A1 (en) 2002-01-24
DE60143058D1 (en) 2010-10-21
EP1476195B1 (en) 2015-05-13
AU2001281415A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
AU2001281416A1 (en) Transportation of nucleic acid substances
NZ608755A (en) Plant support formulation, vehicle for the delivery and translocation of phytologically beneficial substances and compositions containing same
ES2567569T3 (en) Preparation of microbial oil containing polyunsaturated fatty acids
KR20070104596A (en) Production and use of an antioxidant extract from crypthecodinium sp
Bandarra et al. Fatty acids, sterols and α‐tocopherol in Isochrysis galbana
ATE165212T1 (en) DOCOSAHEXAENIC ACID, METHOD FOR THE PRODUCTION THEREOF AND COMPOUNDS CONTAINING IT
JP2004041187A (en) Method for preparing material high in content of long chain polyunsaturated fatty acid
NZ513574A (en) Lipase-catalysed esterification of marine oil
EP2175031A3 (en) Process for preparing highly unsaturated fatty acid and lipid containing highly unsaturated fatty acid
Xue et al. Development prospect and preparation technology of edible oil from microalgae
CN101818179A (en) Method for preparing phosphatidylserine abundant in polyunsaturated fatty acid
CA2481704A1 (en) Astaxanthin medium-chain fatty acid ester, production method of the same, and composition comprising the same
HK1118013A1 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
WO2002005850A3 (en) Enhancement of the action of anti-infective agents
Briand et al. Enzymatic fatty esters synthesis in aqueous medium with lipase from Candida parapsilosis (Ashford) Langeron and Talice
Alakhras et al. Fatty acid lithium salts from Cunninghamella echinulata have cytotoxic and genotoxic effects on HL‐60 human leukemia cells
JP4225783B2 (en) Method for producing γ-linolenic acid from ciliate culture by adding appropriate precursor molecules to the culture medium
Karmee The synthesis, properties, and applications of ascorbyl esters
AU743992B2 (en) Process for producing omega-9 highly unsaturated fatty acid and lipid containing the same
JPH0913075A (en) Oil and fat for diminishing lipid in blood
JP2545480B2 (en) Functional food material
Moovendhan et al. Utilization of cuttlefish liver waste for oil production: evaluation of quality characteristics and biological activity
JP2004091487A (en) Conjugate fatty acid menthol ester and its production method
JP2781395B2 (en) How to fortify Euglena
JPWO2020050304A1 (en) Method for producing docosahexaenoic acid-containing glyceride using lipase hydrolysis reaction